Overview

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

Status:
Recruiting

Trial end date:
2024-08-31

Target enrollment:

Participant gender:

Summary

This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: - Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) - Decitabine, a chemotherapy drug

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Azacitidine
Decitabine
Vaccines